Memorial Sloan Kettering Cancer Center Chief of the Lymphoma Service Gilles Salles Presents Promising New Treatment for Patients With Diffuse Large B-Cell Lymphoma
December 15, 2021
December 15, 2021
NEW YORK, Dec. 15 (TNSJou) -- The Memorial Sloan Kettering Cancer Center issued the following news release on Dec. 14, 2021:
A study from Memorial Sloan Kettering Cancer Center (MSK) published today in the New England Journal of Medicine (NEJM), found that in patients with previously untreated Diffuse Large B-Cell Lymphoma (DLBCL) Polatuzumab vedotin with Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (pola-R-CHP) resulted in a 27 percent reduction in risk of disease progr . . .
A study from Memorial Sloan Kettering Cancer Center (MSK) published today in the New England Journal of Medicine (NEJM), found that in patients with previously untreated Diffuse Large B-Cell Lymphoma (DLBCL) Polatuzumab vedotin with Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (pola-R-CHP) resulted in a 27 percent reduction in risk of disease progr . . .